Comprehensive Screening of Genetic Variants in the Coding Region of <i>F8</i> in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort
Samuel Sarmiento Doncel,
Ronald Guillermo Peláez,
Pablo Lapunzina,
Fernando F. Corrales-Medina,
Gina Alejandra Díaz Mosquera,
Santiago Bonanad,
Javier Mauricio Cortes,
Mario Cazalla,
Natalia Gallego,
Felipe Querol-Giner,
Jair Tenorio,
José A. López Guerrero
Affiliations
Samuel Sarmiento Doncel
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
Ronald Guillermo Peláez
Life Sciences and Health Research Group, Graduates School, CES University, Medellin 050021, Colombia
Pablo Lapunzina
Instituto de Genética Médica y Molecular (INGEMM), IdiPaz, Hospital Universitario La Paz, 28046 Madrid, Spain
Fernando F. Corrales-Medina
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Miami-Miller School of Medicine, Miami, FL 33136, USA
Gina Alejandra Díaz Mosquera
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
Santiago Bonanad
Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain
Javier Mauricio Cortes
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia
Mario Cazalla
Instituto de Genética Médica y Molecular (INGEMM), IdiPaz, Hospital Universitario La Paz, 28046 Madrid, Spain
Natalia Gallego
Instituto de Genética Médica y Molecular (INGEMM), IdiPaz, Hospital Universitario La Paz, 28046 Madrid, Spain
Felipe Querol-Giner
Physiotherapy in Motion Multispeciality Research Group (PTinMOTION), Department of Physiotherapy, University of Valencia, 46010 Valencia, Spain
Jair Tenorio
Instituto de Genética Médica y Molecular (INGEMM), IdiPaz, Hospital Universitario La Paz, 28046 Madrid, Spain
José A. López Guerrero
Doctoral School, Catholic University of Valencia San Vicente Mártir (UCV), 46002 Valencia, Spain
Hemophilia A is an X-linked disorder characterized by quantitative deficiency of coagulation factor VIII (FVIII) caused by pathogenic variants in the factor 8 (F8) gene. Our study’s primary objective was to identify genetic variants within the exonic region of F8 in 50 Colombian male participants with severe hemophilia A (HA). Whole-exome sequencing and bioinformatics analyses were performed, and bivariate analysis was used to evaluate the relationship between identified variants, disease severity, and inhibitor risk formation. Out of the 50 participants, 21 were found to have 17 different pathogenic F8 variants (var). It was found that 70% (var = 12) of them were premature truncation variants (nonsense, frameshift), 17.6% (var = 3) were missense mutations, and 11.7% (var = 2) were splice-site variants. Interestingly, 35% (var = 6) of the identified variants have not been previously reported in the literature. All patients with a history of positive inhibitors (n = 4) were found to have high-impact genetic variants (nonsense and frameshift). When investigating the relationship between variant location (heavy versus light chain) and specific inhibitor risk, 75% (n = 3) of the inhibitor participants were found to have variants located in the F8 light chain (p = 0.075), suggesting that conserved domains are associated with higher inhibitor risk. In summary, we identified genetic variants within the F8 that can possibly influence inhibitor development in Colombian patients with severe HA. Our results provide a basis for future studies and the development of further personalized treatment strategies in this population.